April 20, 2017
Redx Pharma welcoms new Chairman
Redx Pharma has a new Chairman of the Board of Directors and a Non-Executive Director of the company.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
April 20, 2017
BioDynamics joins FNIH Biomakers Consortium
Oxford BioDynamics and its scientific advisory panel member, Dr Claudio Carini will be joining Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium as a member of the Cancer, Inflammation & Immunity, and Neuroscience Steering Committees, the company said Thursday.
April 19, 2017
Cannabidiol may reduce difficult to control seizures
A study showed that cannabidiol shows great promise in that it may reduce seizures that are otherwise difficult to control.
April 19, 2017
Matinas BioPharma welcomes Dominick DiPaolo as Senior VP of Quality and Regulatory Compliance
Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, has appointed Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance.
April 19, 2017
Forward Pharma reports $33M net loss
Forward Pharma has reported financial results for the year ended December 31, 2016.
April 19, 2017
Faron Pharmaceuticals wants to see new names in its board
Faron Pharmaceuticals has decided to add new names to its board, for which the shareholders will decided in May.
April 18, 2017
Faron to test its immuno switch antibody with the University of Birmingham Medical School
Faron Pharmaceuticals and the University of Birmingham Medical School, have signed an agreement to begin a liver cancer program for clinical testing of Faron’s immuno switch antibody Clevegen.
April 18, 2017
Circassia’s house dust mite allergy test gives unexpected result
Circassia Pharmaceuticals’s study of house dust mite allergy immunotherapy phase IIb field study failed to meed its primary endpoint, the company said Tuesday.
April 18, 2017
FDA grants breakthrough therapy designation to Novartis’s B-cell cancer
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’s CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies.
April 18, 2017
FDA nods for Verona’s inhibitor trial
Respiratory diseases biopharmaceutical specialist, Verona Pharma said Tuesday that the U.S. Food and Drug Administration has given the green light for the kick-start of a pharmacokinetic (PK) clinical trial in the U.S. for its RPL554 candidate, with the acceptance of an Investigational New Drug application (IND).